Granulocyte Transfusion Therapy: Survival Directly Correlated with Bone Marrow Recovery and the Pathogenicity of the Infectious Organisms

1981 ◽  
Vol 146 (6) ◽  
pp. 393-396
Author(s):  
James E. Congdon ◽  
Glen R. Justice ◽  
Irwin Dabe ◽  
Eugene P. Flannery ◽  
Michael P. Corder ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Granulocyte Transfusion ◽  
Transfusion Therapy

scholarly journals Granulocyte transfusions: current status

Blood ◽  
1980 ◽  
Vol 55 (1) ◽  
pp. 2-8 ◽  
Author(s):  
DJ Higby ◽  
D Burnett
Keyword(s):  
Bone Marrow ◽  
Acute Leukemia ◽  
Clinical Medicine ◽  
Bone Marrow Failure ◽  
Current Status ◽  
Granulocyte Transfusion ◽  
Transfusion Therapy ◽  
Neutropenic Patients ◽  
Ongoing Evaluation ◽  
Made In

Abstract Since granulocyte transfusions first became widely used in clinical medicine, there have been advances in the treatment of acute leukemia and improvement in prevention and management of infection in neutropenic patients. Improved understanding now exists concerning prognosis of infections in such patients, and advances have been made in procurement of granulocytes. Granulocyte transfusions should be given for specific indications, and used adjunctively to other established antiinfective therapy. Once initiated, transfusions should be given in adequate doses at daily intervals (at least) with ongoing evaluation and periodic reassessment of the whole antiinfective program. Serious complications of granulocyte transfusion therapy are relatively rare, but the physician should be prepared to manage them intelligently. Research continues in discerning exactly how granulocyte transfusion work, in preservation of granulocytes, and in delineation of immunologic phenomena affecting the efficiacy of such therapy. Granulocyte transfusions will continue to be important in the management of acute leukemia, and other reversible bone marrow failure states, and in marrow transplantation and autotransplantation.

scholarly journals Granulocyte transfusions: current status

Blood ◽  
1980 ◽  
Vol 55 (1) ◽  
pp. 2-8
Author(s):  
DJ Higby ◽  
D Burnett
Keyword(s):  
Bone Marrow ◽  
Acute Leukemia ◽  
Clinical Medicine ◽  
Bone Marrow Failure ◽  
Current Status ◽  
Granulocyte Transfusion ◽  
Transfusion Therapy ◽  
Neutropenic Patients ◽  
Ongoing Evaluation ◽  
Made In

Since granulocyte transfusions first became widely used in clinical medicine, there have been advances in the treatment of acute leukemia and improvement in prevention and management of infection in neutropenic patients. Improved understanding now exists concerning prognosis of infections in such patients, and advances have been made in procurement of granulocytes. Granulocyte transfusions should be given for specific indications, and used adjunctively to other established antiinfective therapy. Once initiated, transfusions should be given in adequate doses at daily intervals (at least) with ongoing evaluation and periodic reassessment of the whole antiinfective program. Serious complications of granulocyte transfusion therapy are relatively rare, but the physician should be prepared to manage them intelligently. Research continues in discerning exactly how granulocyte transfusion work, in preservation of granulocytes, and in delineation of immunologic phenomena affecting the efficiacy of such therapy. Granulocyte transfusions will continue to be important in the management of acute leukemia, and other reversible bone marrow failure states, and in marrow transplantation and autotransplantation.

Granulocyte Transfusions in Neonates with Bacterial Infection, Neutropenia, and Depletion of Mature Marrow Neutrophils

PEDIATRICS ◽  
1982 ◽  
Vol 70 (1) ◽  
pp. 1-6
Author(s):  
Robert D. Christensen ◽  
Gerald Rothstein ◽  
Harold B. Anstall ◽  
Blair Bybee
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Adverse Effects ◽  
Bacterial Infection ◽  
Granulocyte Transfusion ◽  
Transfusion Therapy ◽  
Storage Pool ◽  
Marrow Cells

During a three-year period, 26 neonates with bacterial infection and neutropenia were studied. In order to assess the marrow neutrophil reserves, bone marrow aspirates were obtained from each of these patients. The neutrophil storage pool (percent polymorphonuclear + band neutrophils + metamyelocytes in 1,000 nucleated marrow cells) was significantly greater in those who survived their infection (X= 20.1%, range 3.2% to 60.8%) than in those who died (X = 1.9%, range 0.4% to 5.2%, P < .002). In an attempt to improve survival in this group, seven neutrophil-depleted patients with sepsis were given granulocyte transfusions and all survived. In contrast only one of nine nontransfused, neutrophil-depleted infants with sepsis survived (P <.01). The seven granulocyte recipients were examined for possible adverse effects of the transfusions and none were detected. It is suggested that infected, neutropenic neonates with depletion of mature marrow neutrophils are at high risk for death from sepsis, and that these infants may benefit from granulocyte transfusion therapy.

GRANULOCYTE TRANSFUSION THERAPY

1962 ◽  
Vol 1 (20) ◽  
pp. 748-752
Author(s):  
James P. Isbister ◽  
James C. Biggs
Keyword(s):  
Granulocyte Transfusion ◽  
Transfusion Therapy

scholarly journals Bone Marrow Engraftment Analysis after Granulocyte Transfusion

2005 ◽  
Vol 7 (3) ◽  
pp. 422-426 ◽  
Author(s):  
Sharon L. Swierczynski ◽  
Michael J. Hafez ◽  
Juliet Philips ◽  
Meghan A. Higman ◽  
Karin D. Berg ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Granulocyte Transfusion ◽  
Bone Marrow Engraftment

scholarly journals T cell chronic lymphocytic leukemia: presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro

Blood ◽  
1978 ◽  
Vol 52 (1) ◽  
pp. 255-260 ◽  
Author(s):  
R Hoffman ◽  
S Kopel ◽  
SD Hsu ◽  
N Dainiak ◽  
ED Zanjani
Keyword(s):  
Bone Marrow ◽  
T Cell ◽  
Chronic Lymphocytic Leukemia ◽  
T Lymphocytes ◽  
Peripheral Blood ◽  
Lymphocytic Leukemia ◽  
Transfusion Therapy ◽  
Cell Chronic Lymphocytic Leukemia ◽  
Marrow Cells

Abstract The pathogenesis of the anemia associated with malignancy was investigated in a patient with T cell chronic lymphocytic leukemia. The plasma clot culture system was used as a measure in vitro of erythropoiesis. The patient's peripheral blood and marrow T lymphocytes obtained both before and after transfusion therapy suppressed erythroid colony formation by normal human bone marrow cells. Pretreatment of the patient's bone marrow T cells by antithymocyte globulin (ATG) and complement reversed this suppression. In addition, pretreatment of the patient's marrow cells with ATG and complement markedly augmented erythropoiesis in vitro. The expression of erythroid activity caused by the selective destruction of the suppressor T lymphocytes in the patient's bone marrow with ATG and the suppression of normal erythropoiesis by the patient's bone marrow and peripheral blood lymphocytes suggest that interaction between the malignant T cell and the erythropoietin-responsive stem cell is important in production of anemia in this patient.

Granulocyte Transfusion Therapy

1975 ◽  
Vol 26 (1) ◽  
pp. 289-306 ◽  
Author(s):  
D J Higby ◽  
E S Henderson
Keyword(s):  
Granulocyte Transfusion ◽  
Transfusion Therapy

scholarly journals Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670 augments the efficacy of granulocyte transfusion in a clinically relevant mouse model

Blood ◽  
2011 ◽  
Vol 117 (24) ◽  
pp. 6702-6713 ◽  
Author(s):  
Yitang Li ◽  
Amit Prasad ◽  
Yonghui Jia ◽  
Saurabh Ghosh Roy ◽  
Fabien Loison ◽  
...  
Keyword(s):  
Therapeutic Strategy ◽  
Ex Vivo ◽  
Innate Immune ◽  
Innate Immune Responses ◽  
Granulocyte Transfusion ◽  
Chromosome 10 ◽  
Transfusion Therapy ◽  
Phosphatase And Tensin Homolog ◽  
Tensin Homolog ◽  
Bacteria Killing

Abstract The clinical outcome of granulocyte transfusion therapy is often hampered by short ex vivo shelf life, inefficiency of recruitment to sites of inflammation, and poor pathogen-killing capability of transplanted neutrophils. Here, using a recently developed mouse granulocyte transfusion model, we revealed that the efficacy of granulocyte transfusion can be significantly increased by elevating intracellular phosphatidylinositol (3,4,5)-trisphosphate signaling with a specific phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670. Neutrophils treated with SF1670 were much sensitive to chemoattractant stimulation. Neutrophil functions, such as phagocytosis, oxidative burst, polarization, and chemotaxis, were augmented after SF1670 treatment. The recruitment of SF1670-pretreated transfused neutrophils to the inflamed peritoneal cavity and lungs was significantly elevated. In addition, transfusion with SF1670-treated neutrophils led to augmented bacteria-killing capability (decreased bacterial burden) in neutropenic recipient mice in both peritonitis and bacterial pneumonia. Consequently, this alleviated the severity of and decreased the mortality of neutropenia-related pneumonia. Together, these observations demonstrate that the innate immune responses can be enhanced and the severity of neutropenia-related infection can be alleviated by augmenting phosphatidylinositol (3,4,5)-trisphosphate in transfused neutrophils with PTEN inhibitor SF1670, providing a therapeutic strategy for improving the efficacy of granulocyte transfusion.

Sign in / Sign up

Export Citation Format

Share Document